한글목차

조직학 및 세포학은 세포, 조직 및 장기에 대한 중요한 인사이트를 제공하며 병리 검사실에서 오랫동안 필수적인 요소였습니다. 병리조직검사를 통해 암을 포함한 다양한 질병을 정확하게 진단할 수 있습니다. 의사들은 치료 계획과 예후를 결정하기 위해 병리학적 정보에 크게 의존하고 있습니다.

최근의 기술 발전은 조직과 장기의 구조와 기능의 관계 및 질병과의 연관성에 대한 이해를 크게 향상시켰습니다. 디지털 이미지, 정량 현미경, 정밀 현미경, 인공지능, 가상 조직학 등의 기술 혁신은 조직학/세포학 산업에 혁명을 일으켜 정확도 향상과 워크플로우의 자동화를 실현하고자 합니다.

이 보고서는 조직학 및 세포학 IVD 시장을 조사하여 2023년 시장 현황과 2028년까지의 예측을 수록하고 있습니다. 또한, 경쟁 분석과 지역별 동향에 대한 분석도 수록되어 있습니다.

목차

제1장 주요 요약

제2장 시장 개요

• 조직학/세포학 개요
• 조직학과 암
• 고급 분석 솔루션
• 연구실 개발 테스트
• AI와 조직학

제3장 시장 규모와 성장

• 시장 부문
• 전통적인 조직 염색
• PAP 검사
• 면역조직화학과 ISH(In Situ Hybridization)
• HPV
• 지역별 시장
• 북미
• 유럽
• 아시아태평양
• 기타 지역
• 경쟁 분석
• 조직학의 상업적 전망

제4장 주요 시장 진출 기업

• Abbott Diagnostics
• Agilent
• Becton, Dickinson and Company
• Biocare Medical
• BioGenex
• Danaher Corporation
• Hologic
• Illumina, Inc
• Medimeas
• QIAGEN N.V.
• Roche Diagnostic
• Sysmex
• Thermo Fisher Scientific

영문목차

"Histology and Cytology IVD Market Update, 2024" provides an in-depth competitive analysis of the histology/cytology market from 2023 to 2028. The forecasted market analysis from 2023 to 2028 is based on demographic trends, new technological developments, innovative products, and global market expansion. This comprehensive review offers insights into the future direction of the histology and cytology IVD market, highlighting the potential for growth and advancements.

Histology and cytology have long been essential components of pathological laboratories, offering critical insights into cells, tissues, and organs. Through histopathological examinations, a variety of diseases, including cancer, can be accurately diagnosed. Physicians rely heavily on pathological information to determine treatment plans and prognoses.

Technological Advancements

Recent technological advancements have significantly enhanced the understanding of tissue and organ structure-function relationships and their link to diseases. Innovations such as digital imaging, quantitative microscopy, precision microscopy, artificial intelligence, and virtual histology are set to revolutionize the histology/cytology industry, improving accuracy and automating workflows.

Market Segmentation

This report exclusively focuses on traditional histology and segments the market into five key areas:

Key Market Participants

The report also profiles five leading companies in the market:

Market Data

All market data pertains to the global market at the manufacturers' level, focusing on manufacturer tests. The base year for data is 2023, with projections for 2028. The report provides compound annual growth rates (CAGRs) for 2023-2028. Additionally, competitive analysis and regional breakdowns for the United States, Europe, Asia-Pacific, and the Rest of the World are included.

Table of Contents

Chapter 1: Executive Summary

• Industry at a Glance
• Scope and Methodology
• Size and Growth of the Market
  • Figure 1-1: Global Histology IVD Market, 2023-2028 ($ millions)
• Competitive Outlook

Chapter 2: Market Overview

• Overview Of Histology/Cytology
• Histology and Cancer
• Advanced Analysis Solutions
  • Table 2-1: Selected Advanced Histology Techniques
• Laboratory Developed Tests
• AI and Histology

Chapter 3: Market Size and Growth

• Market Segments
  • Table 3-1: Global Histology/Cytology Sales, by Type (Pap Tests, In situ hybridization, Immunohistochemistry, Traditional non-Pap stains, HPV), 2023-2028 ($ millions)
  • Figure 3-1: Global Histology/Cytology IVD Market, 2023-2028 ($ millions)
  • Figure 3-2: Histology/Cytology Diagnostic Market Distribution, by Broad Test Category (Pap Tests, In situ hybridization, Immunohistochemistry, Traditional non-Pap stains, HPV), 2023 (%)
• Traditional Tissue Stains
  • Table 3-2: Selected Vendors of Traditional Histology Stains
• PAP Tests
  • Table 3-3: Primary and Secondary Prevention of Cervical Cancer, Screening Responses by Country, 2022 (last updated 2022-5-6)
• Immunohistochemistry and In Situ Hybridization
  • Table 3-4: Selected in Situ Hybridization-based Tests
  • Table 3-5: Selected IHC Test Innovations
• HPV
  • Figure 3-3: HPV Screening Market: HPV DNA and Pap Test Distribution of Sales, 2023
  • Table 3-6: Global HPV Molecular (DNA/RNA) Test Sales Distribution, by Region (North America, Europe, Asia Pacific, RoW), 2023 (%)
  • Table 3-7: Selected HPV Test Innovations
• Market by Region
  • Table 3-8: Global Histology/Cytology Market, by Region (North America, Europe, Asia, RoW), 2023-2028 ($ millions)
  • Figure 3-4: Global Histology/Cytology Market, by Region (North America, Europe, Asia, RoW), 2023-2028 (%)
  • Table 3-9: Global Histology/Cytology Sales Distribution, by Region (North America, Europe, Asia Pacific, RoW), 2023 (%)
• North America
  • Table 3-10: North America Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
  • Figure 3-5: North America Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
• Europe
  • Table 3-11: Europe Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
  • Figure 3-6: Europe Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
• Asia Pacific
  • Table 3-12: Asia Pacific Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
  • Figure 3-7: Asia Pacific Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
• Rest of World (RoW)
  • Table 3-13: Rest of World (RoW) Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 ($ millions)
  • Figure 3-8: Rest of World (RoW) Histology/Cytology Market, by Segment (Pap Test, In situ hybridization, Immunohistochemistry, Traditional non-Pap test, HPV-DNA), 2023-2028 (%)
• Competitive Analysis
  • Table 3-14: Revenues of the Major Histology Companies, 2017-2023 ($ millions, estimated)
  • Table 3-15: Pathology Launches by Roche
• The Commercial Outlook for Histology

Chapter 4: Major Market Participants

• Abbott Diagnostics
  • Table 4-1: Abbott Corporate Summary
  • Table 4-2: Abbott Revenue History, 2017-2023 ($ million)
• Agilent
  • Table 4-3: Agilent Corporate Summary
  • Table 4-4: Agilent Diagnostic Revenues, 2017-2023 ($ millions)
  • Figure 4-1: Agilent Revenues, by Group, 2022-2023 ($ millions)
• Becton, Dickinson and Company
  • Table 4-5: Becton Dickinson Corporate Summary
  • Table 4-6: BD Revenue History, 2017-2023 ($ million, FYE Sept 30)
• Biocare Medical
  • Table 4-7: Biocare Medical Corporate Summary
• BioGenex
  • Table 4-8: BioGenex Corporate Summary
• Danaher Corporation
  • Table 4-9: Danaher Corporation Summary
  • Table 4-10: Danaher Revenue History, 2017-2023 ($ million, estimated)
  • Figure 4-2: Danaher Diagnostics (Recurring/Nonrecurring), Full Year 2022 and 2023 ($ millions)
• Hologic
  • Table 4-11: Hologic Corporate Summary
  • Table 4-12: Hologic Revenue History, 2017-2023 ($ million, estimated)
  • Figure 4-3: Hologic Diagnostic Product Revenues, FY 2022 and FY 2023 ($ million)
• Illumina, Inc
  • Table 4-13: Illumina Corporate Summary
  • Table 4-14: Illumina Diagnostics Revenues, 2017-2023 ($ millions)
  • Figure 4-4: Illumina Diagnostic Revenues, 2022-2023 ($ millions)
• Medimeas
  • Table 4-15: Medimeas Corporate Summary
• QIAGEN N.V.
  • Table 4-16: QIAGEN Corporate Summary
  • Table 4-17: QIAGEN Revenue History, 2017-2023 ($ million, estimated)
• Roche Diagnostic (Roche Tissue Diagnostics)
  • Table 4-18: Roche Diagnostic Corporate Summary
  • Table 4-19: Roche Revenue History ($ million, estimated)
  • Figure 4-5: Roche Diagnostic Performance, Full Year 2022 and 2023 (CHF Mn)
• Sysmex
  • Table 4-20: Sysmex Corporate Summary
  • Table 4-21: Sysmex Revenue History, 2017-2023 ($ million, estimated)
• Thermo Fisher Scientific
  • Table 4-22: Thermo Fisher Corporate Summary
  • Table 4-23: Thermo Fisher Revenue History, 2017-2023 ($ million, estimated)